novartis signs up poh's tpm, page-11

Hi JP,

In regards to PNO and OBJ you may be interested in the following abstract from OBJ's recent Appendix 4D...

Prototype development and testing is advancing and initial encouraging results have been achieved by the company's new proprietary formulation

In regards to POH and the Novartis deal signed with POH's Indian partner, Themis Medicare on March 26 this year, no doubt POH will release a nice announcement for its s/holders today, however more recent news from Novartis suggests that the celebrations may be short lived...

Novartis boss: Drugs investment 'will cease in India'

The head of Novartis India, Ranjit Shahani, has said the company was "disappointed" that India's Supreme Court refused to grant a patent for an updated version of its cancer drug Glivec.

Speaking to the BBC's India Business Report, Mr Shahani said that his company would not invest drugs research and development in India in the future, and suggested that other pharmaceutical firms would follow suit.

The drugmaker was denied a patent on the grounds that the new version of Glivec was only slightly different from the old. The decision means generic drugmakers can continue to sell copies of the drug at a lower price in India. - BBC News

For POH holders I hope this isn't the case, however India's Supreme Court ruling over Novartis cancer drug Glivec does carru implications for risk protection over new formulations of existing pharmaceutical products.



This was on the same thread ( pno) as my previous post

I am hoping this afternoon brings big smiles for all us pohsters!!